Pharmacokinetics and pharmacogenomics of daunorubicin in children: A report from the Children's Oncology Group

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 4, 2014, Pages 831-838

  Thompson, Patrick ^a   Wheeler, Heather E ^b   Delaney, Shannon M ^b   Lorier, Rachel ^c   Broeckel, Ulrich ^c   Devidas, Meenakshi ^a   Reaman, Gregory H ^d   Scorsone, Kathleen ^a   Sung, Lillian ^e   Dolan, M Eileen ^b   Berg, Stacey L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Body composition; Daunorubicin; Daunorubicinol; Obesity; Pediatrics; Pharmacogenetics; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DAUNORUBICIN; DAUNORUBICINOL; DIMETHYLANILINE MONOOXYGENASE (N-OXIDE FORMING); GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, HUMAN; OXYGENASE;

ANALOGS AND DERIVATIVES; BODY COMPOSITION; BODY MASS; CHILD; COMPLICATION; DRUG SCREENING; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETICS; HAPLOTYPE; HUMAN; MALE; METABOLIC CLEARANCE RATE; NEOPLASMS; OBESITY; PHARMACOGENETICS; PHOTON ABSORPTIOMETRY; STATISTICAL MODEL;

ABSORPTIOMETRY, PHOTON; ANTIBIOTICS, ANTINEOPLASTIC; BODY COMPOSITION; BODY MASS INDEX; CHILD; DAUNORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GLUTATHIONE S-TRANSFERASE PI; HAPLOTYPES; HUMANS; MALE; METABOLIC CLEARANCE RATE; MODELS, STATISTICAL; NEOPLASMS; OBESITY; OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84939890862     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2535-4     Document Type: Article

References (43)

1. Robert J (1998) Anthracyclines. In: Grochow LB, Ames MM (eds) A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics. Williams and Wilkins, Baltimore, pp 93-173
2. Kuffel MJ, Ames MM (1995) Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 Cells. Cancer Chemother Pharmacol 36:223-226
3. Boucek RJ Jr, Olson RD, Boucek DE et al (1987) The major metabolite of doxorubicin is a potent inhibitor of membraneassociated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem 262:15851-15856
4. Olson RD, Mushlin PS, Brenner DE et al (1988) Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci U S A 85:3585-3589
5. Cusack BJ, Young SP, Driskell J et al (1993) Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 32:53-58
6. Mushlin PS, Cusack BJ, Boucek RJ Jr et al (1993) Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br J Pharmacol 110:975-982
7. Stewart DJ, Grewaal D, Green RM et al (1993) Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues. Anticancer Res 13:1945-1952
8. Forrest GL, Gonzalez B, Tseng W et al (2000) Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 60:5158-5164
9. Wang GX, Wang YX, Zhou XB et al (2001) Effects of doxorubicinol on excitation-contraction coupling in guinea pig ventricular myocytes. Eur J Pharmacol 423:99-107
10. Olson LE, Bedja D, Alvey SJ et al (2003) Protection from doxo-rubicin- induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res 63:6602-6606
11. Lal S, Mahajan A, Chen WN et al (2010) Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab 11:115-128
12. Ueda K, Cardarelli C, Gottesman MM et al (1987) Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A 84:3004-3008
13. Sharma R, Singhal SS, Cheng J et al (2001) RLIP76 is the major ATP-dependent transporter of glutathione-conjugates and doxorubicin in human erythrocytes. Arch Biochem Biophys 391:171-179
14. Okabe M, Unno M, Harigae H et al (2005) Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 333:754-762
15. Lal S, Sandanaraj E, Wong ZW et al (2008) CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99:2045-2054
16. Sandanaraj E, Lal S, Selvarajan V et al (2008) PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin Cancer Res 14:7116-7126
17. Rocha JC, Cheng C, Liu W et al (2005) Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105:4752-4758
18. Pander J, Gelderblom H, Guchelaar HJ (2007) Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs. Expert Opin Pharmacother 8:1197-1210
19. Lange BJ, Gerbing RB, Feusner J et al (2005) Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 293:203-211
20. Hijiya N, Panetta JC, Zhou Y et al (2006) Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood 108:3997-4002
21. Palle J, Frost BM, Peterson C et al (2006) Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. Anticancer Drugs 17:385-392
22. Thompson PA, Rosner GL, Matthay KK, et al. (2008) Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser pediatric research network study. Cancer Chemother Pharmacol
23. Berg S, Cowan K, Balis F et al (1994) Pharmacokinetics of Taxol and Doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 86:143-145
24. Dobbs N, James C (1987) Estimation of doxorubicin and doxorubicinol by high performance liquid chromatography and advanced automated sample processor. J Chromatogr Biomed Appl 420:184-188
25. Hempel G, Relling MV, de Rossi G et al (2010) Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Pediatr Blood Cancer 54:355-360
26. Purcell S, Neale B, Todd-Brown K et al (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559-575
27. Callies S, de Alwis DP, Mehta A et al (2004) Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979). Cancer Chemother Pharmacol 54:39-48
28. Mannervik B, Alin P, Guthenberg C et al (1985) Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. Proc Natl Acad Sci U S A 82:7202-7206
29. O'Brien M, Kruh GD, Tew KD (2000) The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J Pharmacol Exp Ther 294:480-487
30. Hayes JD, Pulford DJ (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30:445-600
31. Marciniak P, Drobnik K, Ziemnicka K et al (2006) Transferase S-glutathione class pi gene (GSTP1) polymorphism in thyroid cancer patients. Endokrynol Pol 57:509-515
32. Ali-Osman F, Akande O, Antoun G et al (1997) Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 272:10004-10012
33. Romero A, Martin M, Oliva B, et al. (2011) Glutathione S-transferase P1 c.313A>G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients. Ann Oncol
34. Dasgupta RK, Adamson PJ, Davies FE et al (2003) Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 102:2345-2350
35. Sweeney C, McClure GY, Fares MY et al (2000) Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 60:5621-5624
36. Stoehlmacher J, Park DJ, Zhang W et al (2002) Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94:936-942
37. Hohaus S, Di Ruscio A, Di Febo A et al (2005) Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res 11:2175-2179
38. Stanulla M, Schaffeler E, Arens S et al (2005) GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int J Hematol 81:39-44
39. Ramos DL, Gaspar JF, Pingarilho M et al (2011) Genotoxic effects of doxorubicin in cultured human lymphocytes with different glutathione S-transferase genotypes. Mutat Res 724:28-34
40. Hisamuddin IM, Yang VW (2007) Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives. Pharmacogenomics 8:635-643
41. Soderberg MM, Haslemo T, Molden E, et al. (2012) Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients. Pharmacogenomics J
42. Lal S, Wong ZW, Sandanaraj E et al (2008) Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99:816-823
43. Lal S, Wong ZW, Jada SR et al (2007) Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics 8:567-575